Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
- Conditions
- Interventions
- Procedure: BiopsyDrug: Bendamustine HydrochlorideProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyProcedure: Multigated Acquisition ScanDrug: LenalidomideDrug: CyclophosphamideBiological: ObinutuzumabDrug: Doxorubicin HydrochlorideProcedure: Positron Emission TomographyDrug: UmbralisibDrug: PrednisoneDrug: Vincristine Sulfate
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 95
- Registration Number
- NCT03269669
- Locations
- 🇺🇸
Longmont United Hospital, Longmont, Colorado, United States
🇺🇸Rocky Mountain Cancer Centers-Longmont, Longmont, Colorado, United States
🇺🇸Banner McKee Medical Center, Loveland, Colorado, United States
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2017-08-17
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 53
- Registration Number
- NCT03252600
- Locations
- 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Levine Cancer Center, Charlotte, North Carolina, United States
🇺🇸Emory Winship Cancer Institute, Atlanta, Georgia, United States
Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03232307
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- Singapore General Hospital
- Registration Number
- NCT03212807
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇸🇬Raffles Hospital, Singapore, Singapore
🇸🇬Singapore General Hospital, Singapore, Singapore
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- University of Leeds
- Registration Number
- NCT03191981
- Locations
- 🇬🇧
University College Hospital, London, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Southampton General Hospital, Southampton, United Kingdom
MUK Nine b: OPTIMUM Treatment Protocol
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 95
- Registration Number
- NCT03188172
- Locations
- 🇬🇧
Bristol Haematology & Oncology Centre, Bristol, United Kingdom
🇬🇧Queen Elizabeth Hospital, Birmingham, United Kingdom
🇬🇧Birmingham Heartlands Hospital, Birmingham, United Kingdom
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 141
- Registration Number
- NCT03173092
- Locations
- 🇺🇸
Saint Agnes Hospital, Baltimore, Maryland, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Pacific Cancer Medical Center, Anaheim, California, United States
2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03168100
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT03118466
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts general Hospital, Boston, Massachusetts, United States
Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 4
- Registration Number
- NCT03113695
- Locations
- 🇺🇸
University of California, San Diego, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.